
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax Inc has shown a slight increase in its fiscal year 2025 revenue outlook, with projections raised to a range of $1.04 billion to $1.06 billion, reflecting confidence in market opportunities. The company has secured $225 million in milestones from SNY, with an additional $50 million anticipated in the fourth quarter of 2025, which is expected to enhance cash flow and operational funding. Furthermore, an improvement in working capital to $544.7 million and cost-saving measures projected to yield approximately $230 million over the next 11 years signal a robust financial position, supporting Novavax's strategic focus on early-stage vaccine development and partnerships.
Bears say
Novavax Inc. is facing significant challenges that contribute to a negative outlook on its stock, primarily due to operational setbacks and declining financial metrics. The company's cash equivalents decreased to $778.2 million from $938.2 million, driven by operational cash burn and a 17% year-over-year revenue decline, largely attributed to the transition of lead commercial responsibility to Sanofi beginning with the 2025-2026 COVID season. Additionally, ongoing concerns regarding the competitiveness of its vaccine candidates, such as NanoFlu, hinder future revenue generation, especially if these candidates fail to demonstrate differentiation from existing options, which could severely impact the company's financial forecasts and overall valuation.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares